We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 15, 2021

Pembrolizumab Monotherapy for the Treatment of High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study
Lancet Oncol 2021 May 26;[EPub Ahead of Print], AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, LEM Krieger, EA Singer, DF Bajorin, P Grivas, HK Seo, H Nishiyama, BR Konety, H Li, K Nam, E Kapadia, T Frenkl, R de Wit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading